5AM Ventures
5AM Ventures is a venture capital firm that aims to finance seed and early-stage life sciences companies.
Business Model:
Revenue: $5.5M
Employees: 2-10
Rankings
Industries / Tags:
Detailed 5AM Ventures Information
Geographic Data
Address: 501 Second Street
City: San Francisco
State: CA
Zip: 94107
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,748,000Website Global Rank
6,291Website Monthly Traffic
Twitter Followers
Description
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Contact Phone:
+14159938570
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2022 | Novome | Series B | 0 |
| 9/2013 | Arvinas | Series A | 15M |
| 7/2021 | TMRW Life Sciences | Series C | 105M |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 9/2015 | Precision NanoSystem | Series A | 0 |
| 1/2017 | GenePeeks | Series B | 0 |
| 1/2019 | Pear Therapeutics | Series C | 64M |
| 9/2021 | RareCyte | Series G | 0 |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 12/2020 | Pear Therapeutics | Series D | 0 |
| 7/2018 | Nohla Therapeutics | Series B | 11M |
| 4/2018 | Rallybio | Series A | 37M |
| 6/2014 | Chrono Therapeutics | Series A | 32M |
| 1/2015 | IDEAYA Biosciences | Seed Round | - |
| 3/2013 | Achaogen | Series D | 18.9M |
| 4/2020 | Rallybio | Series B | 0 |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 3/2014 | scPharmaceuticals | Series A | 16M |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 12/2013 | Bellerophon Therapeutics | Series A | 0 |
| 11/2021 | GlycoEra | Series A | 0 |
| 1/2006 | Ambrx | Series B | 5M |
| 11/2017 | Nouscom | Series B | 48.8M |
| 5/2014 | Ceterix Orthopaedics | Series B | 18M |
| 8/2021 | Neurogastrx | Series B | 60M |
| 1/2016 | BlueLight Therapeutics | Series B | 10M |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 12/2021 | Pear Therapeutics | Post-IPO Equity | 0 |
| 1/2009 | Igenica | Series A | 3.1M |
| 3/2018 | Novome Biotechnologies | Seed Round | 4.5M |
| 8/2004 | Kalypsys | Series B | 29M |
| 4/2012 | Epirus Biopharmaceuticals | Venture Round | 8.1M |
| 3/2005 | Ambrx | Series A | 23.4M |
| 10/2012 | Pearl Therapeutics | Private Equity Round | 23.3M |
| 4/2005 | Ikaria | Series A | 10M |
| 12/2018 | Entrada Therapeutics | Series A | 59M |
| 11/2016 | Nohla | Series A | 43.5M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 9/2020 | Nido Biosciences | Venture Round | 18.4M |
| 4/2022 | Dianthus Therapeutics | Series A | 0 |
| 1/2008 | Anaphore | Venture Round | 3.3M |
| 11/2020 | Inipharm | Series A | 0 |
| 1/2007 | VBI Vaccines | Series A | 35.7M |
| 1/2009 | Synosia Therapeutics | Series B | 0 |
| 8/2017 | RareCyte | Venture Round | 30M |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 10/2015 | Portal Instruments | Series B | 25M |
| 5/2016 | IDEAYA Biosciences | Series A | 46M |
| 7/2008 | Pearl Therapeutics | Series A | 18M |
| 5/2015 | Spyryx Biosciences | Series A | 18.2M |
| 10/2010 | Pearl Therapeutics | Series C | 69M |
| 4/2010 | Achaogen | Series C | 56M |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 9/2010 | Relypsa | Series B | 70M |
| 1/2019 | Enliven Therapeutics | Seed Round | - |
| 10/2021 | Radionetics Oncology | Private Equity Round | 30M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 8/2016 | Cleave Therapeutics | Series B | 0 |
| 6/2010 | Igenica | Series B | 24M |
| 1/2017 | scPharmaceuticals | Series B | 45.6M |
| 1/2017 | Halio | Series C | 65M |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 6/2012 | Igenica | Series C | 33M |
| 10/2015 | Arvinas | Series B | 41.6M |
| 11/2011 | Cleave Therapeutics | Series A | 42M |
| 1/2018 | Neurogastrx | Series A | 45M |
| 7/2012 | Vifor Pharma | Private Equity Round | 0 |
| 2/2010 | Pearl Therapeutics | Series C | 15M |
| 10/2012 | Relypsa | Venture Round | 2.6M |
| 8/2011 | Relypsa | Series B | 70.1M |
| 7/2013 | Audentes Therapeutics | Series A | 30M |
| 8/2019 | Cleave Therapeutics | Series C | 0 |
| 12/2016 | Impel NeuroPharma | Series C | 36M |
| 2/2023 | Spruce Biosciences | Post-IPO Equity | 0 |
| 6/2019 | Purigen Biosystems | Series B | 26.4M |
| 5/2007 | Marcadia Biotech | Series A | 15M |
| 11/2020 | Kinaset Therapeutics | Series A | 40M |
| 6/2020 | Artiva Biotherapeutics | Series A | 0 |
| 1/2019 | Cabaletta Bio | Series B | 0 |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 7/2006 | Ambrx | Series C | 52M |
| 12/2020 | Enliven Therapeutics | Series A | 55M |
| 12/2018 | Impel NeuroPharma | Series D | 67.5M |
| 8/2012 | Vifor Pharma | Series C | 0 |
| 6/2018 | NodThera | Series A | 40M |
| 3/2006 | Marcadia Biotech | Venture Round | 1M |
| 9/2019 | Nido Biosciences | Seed Round | 4M |
| 9/2016 | Chrono Therapeutics | Series B | 47.6M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 10/2010 | Synosia Therapeutics | Series C | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 1/2007 | Synosia Therapeutics | Venture Round | 32.5M |
| 12/2018 | Magnetic Insight | Series A | 13M |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 12/2014 | Audentes Therapeutics | Series B | 42.5M |
| 5/2019 | CinCor Pharma | Series A | 50M |
| 2/2008 | PhaseRx | Series A | 20.2M |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
| 2/2016 | Pear Therapeutics | Series A | 20M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 5/2016 | Purigen Biosystems | Series A | 18.2M |
| 1/2018 | Pear Therapeutics | Series B | 50M |
| 6/2022 | Magnetic Insight | Series B | 0 |
| 4/2018 | Arvinas | Series C | 55M |
| 12/2010 | Semprus BioSciences | Series B | 18M |
| 1/2014 | Igenica | Series C | 14M |
| 9/2008 | Humanigen | Series D | 0 |
| 10/2004 | Miikana Therapeutics | Series A | 3M |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 8/2011 | Pulmatrix | Series B | 14M |
| 6/2015 | Pulmatrix | Post-IPO Equity | 10M |
| 11/2009 | Pulmatrix | Series B | 30.2M |
| 3/2005 | Humanigen | Series B | 20M |
| 1/2023 | Ensoma | Series B | 0 |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 6/2020 | NodThera | Series B | 55M |
| 5/2018 | Escient Pharmaceuticals | Series A | 40M |
| 10/2019 | Wildcat Discovery Technologies | Series C | 0 |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 3/2020 | Akouos | Series B | 105M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 8/2018 | Akouos | Series A | 25.1M |
| 6/2021 | CAMP4 Therapeutics | Series A | 0 |
| 10/2009 | Envoy Therapeutics | Series A | 8M |
| 5/2017 | Scientist.com | Series C | 0 |
| 11/2018 | Aprea | Series C | 0 |
| 10/2006 | Achaogen | Series B | 26M |
| 4/2008 | Bird Rock Bio | Series A | 8M |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 7/2022 | CAMP4 Therapeutics | Series B | 0 |
| 5/2016 | Homology Medicines | Series A | 43.5M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 10/2012 | Halio | Venture Round | 7M |
| 6/2010 | Incline Therapeutics | Series A | 43M |
| 10/2008 | S*Bio | Venture Round | 26M |
| 8/2015 | Calibrium | Convertible Note | 1.7M |
| 7/2011 | DVS Sciences | Series A | 14.6M |
| 3/2016 | Aprea | Series B | 50.6M |
| 4/2010 | Viveve | Venture Round | 4M |
| 4/2009 | Ambrx | Series D | 10M |
| 4/2008 | Anaphore | Venture Round | 8M |
| 1/2009 | Anaphore | Series A | 25M |
| 2/2019 | Vor Biopharma | Series A | 42M |
| 3/2013 | Novira Therapeutics | Series A | 0 |
| 6/2009 | Anaphore | Series A | 13M |
| 3/2014 | Bird Rock Bio | Series B | 0 |
| 12/2019 | RareCyte | Equity | 22M |
| 3/2009 | Pulmatrix | Series A | 3.5M |
| 5/2023 | Carmot Therapeutics | Series E | 0 |
| 1/2009 | Bird Rock Bio | Series A | 25M |
| 12/2019 | TMRW Life Sciences | Series B | 36.5M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 10/2013 | BlueLight Therapeutics | Series A | 15M |
| 12/2008 | Humanigen | Series D | 12M |
| 11/2018 | Cabaletta Bio | Series A | 38M |
| 5/2003 | Ilypsa | Series A | 8M |
| 6/2018 | Precision NanoSystem | Series B | 6M |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 5/2015 | Viveve | Post-IPO Equity | 12M |
| 3/2015 | Pear Therapeutics | Venture Round | - |
| 10/2003 | Miikana Therapeutics | Series A | 4.3M |
| 3/2009 | Rennovia | Series A | 16.3M |
| 4/2013 | Pearl Therapeutics | Venture Round | 41.7M |
| 7/2012 | Epirus Biopharmaceuticals | Venture Round | 5M |
| 4/2014 | Epirus Biopharmaceuticals | Series B | 36M |
| 9/2003 | Ambrx | Series A | 12.5M |
| 1/2019 | Halio | Series D | 100M |
| 9/2007 | Pearl Therapeutics | Series A | 15.5M |
| 11/2012 | Pearl Therapeutics | Series D | 65M |
| 11/2017 | Akouos | Seed Round | 7.5M |
| 12/2008 | Semprus BioSciences | Series A | 8M |
| 4/2012 | Viveve | Venture Round | 7.2M |
| 10/2007 | Relypsa | Series A | 33M |
| 7/2022 | CAMP4 Therapeutics | Series B | 0 |
| 6/2022 | Magnetic Insight | Series B | 0 |
| 4/2022 | Dianthus Therapeutics | Series A | 0 |
| 12/2021 | Pear Therapeutics | Post-IPO Equity | 0 |
| 11/2021 | GlycoEra | Series A | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 0 |
| 9/2021 | RareCyte | Series G | 0 |
| 9/2021 | Disc Medicine | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
